Feed PHVS
PH

Pharvaris N.V.

PHVS · NASDAQ

$36.02 -0.85% (-$0.31)
1M -3.46%
Market Cap 2.20B €
P/E Ratio -
Div. Yield -
ROE 61.24%

Bulios Fair Price

$29.96

16.8% downside

Trenutna cena

$36.02

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PHVS trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
9 /100
Expensive
P/B 7.30x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 22.04%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 61.56%
Asset turnover 0.00x
ROE 61.24%
Debt
69 /100
Low
Debt/Equity 0.00x
Int. coverage -1,068.31x
Current ratio 11.94x
Stability
62 /100
Moderate
Beta -2.32x
Profitable years 0
EPS volatility 13.71%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PHVS
Online

O podjetju

Pharvaris N.V. (PHVS) is a biotechnology company focused on developing innovative drugs for the treatment of rare diseases, particularly angioedema disorders. The company utilizes advanced technologies and modern approaches to discover new drug candidates that can improve the quality of life for patients suffering from these conditions. Pharvaris N.V. is focused on developing drugs targeting specific molecular mechanisms that can provide effective treatment with minimal side effects. Shares of Pharvaris N.V. (PHVS) could be an intriguing investment opportunity for investors monitoring the biotechnology sector and seeking companies with the potential to change the therapeutic paradigm for a range of diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Berndt Modig

Employees

148

Headquarters

Zug

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

50d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.